In clinical research, the manufacture and presentation of investigational medicinal products (IMPs) are as critical as the study design itself. Among the most strategically important yet often underestimated activities are encapsulation and over-encapsulation processes that directly influence product quality, patient safety, and the scientific validity of blinded clinical trials.
What Are Encapsulation and Over-Encapsulation?
Encapsulation involves placing an active drug or placebo into a capsule shell to create a uniform, trial-ready oral dosage form.
Over-encapsulation goes a step further: an existing tablet, capsule, or caplet is enclosed within an opaque hard capsule shell, often with a small amount of inert backfill to eliminate empty space and equalize weight across treatment arms.
This is especially valuable when a comparator product or varying strengths must be made visually and physically indistinguishable from an investigational product.
Why Over-Encapsulation Is Essential
The primary driver is blinding. In randomised controlled trials, blinding protects the study from bias by ensuring that patients, investigators, and site teams cannot identify which treatment is active, placebo, or comparator. Without effective blinding, subjective endpoint reporting, dosing behaviour, and investigator assessments can be unintentionally influenced.
Over-encapsulation masks differences in colour, size, markings, tactile feel, and even sound, factors more influential than many teams realise. However, robust blinding must never compromise product performance. Comparative dissolution and disintegration testing are therefore essential to confirm that the over-encapsulated dosage form releases drug in a manner equivalent to the original.
Technical and Quality Considerations
Over-encapsulation introduces several practical and GMP-critical considerations:
- Capsule selection and backfill: Capsules must be inert and appropriately sized. Backfill excipients such as microcrystalline cellulose or lactose help standardise weight and prevent subjects from detecting differences by touch.
- Dissolution and stability: Adding a capsule shell can alter disintegration time or create moisture-related risks. Dissolution testing and appropriate stability studies are required to ensure the modified product maintains its safety and efficacy profile.
- Mix-up prevention: When multiple strengths or products are handled on the same packaging line, segregation, line clearance, and reconciliation procedures are critical to avoid cross-contamination or inadvertent unblinding.
- Traceability and emergency unblinding: A robust system must allow rapid unblinding by authorised personnel in urgent safety situations, without exposing treatment allocation broadly.
Regulatory Context: EU GMP Annex 13
EU GMP Annex 13, explicitly recognises that IMPs may require repackaging or modification, including encapsulation and over-encapsulation. Because such manipulation is considered manufacturing, it must take place at an authorised IMP facility, under a validated and controlled process, and be certified by a Qualified Person (QP) before use in a clinical trial.
Annex 13 also requires:
- A detailed product specification file (PSF),
- Validated analytical and packaging controls,
- Procedures ensuring blinding integrity,
- Full traceability across the product lifecycle.
Strategic Value for Sponsors and IMP Service Providers
By partnering with Eramol we can offer experienced IMP services reduce risk, shorten timelines, and ensure compliance with Annex 13. Within our end-to-end service offering we can demonstrate expertise in encapsulation, over-encapsulation, blinding strategy, secondary packaging, labelling, storage and distribution, and QP oversight which makes us a powerful differentiator in a competitive market.